El Salvador vs South-East Asia (WHO region): Hypertension: effective treatment coverage (controlled hypertension)
El Salvador
39.5%
in 2019
South-East Asia (WHO region)
13.3%
in 2019
El Salvador rank
10th
South-East Asia (WHO region) rank
13th
Hypertension: effective treatment coverage (controlled hypertension) over time
- El Salvador
- South-East Asia (WHO region)
How they compare
El Salvador currently reports 39.5% against 13.3% in South-East Asia (WHO region), a difference of 26.2%.
That makes El Salvador's figure about 3.0 times South-East Asia (WHO region)'s.
Across all 30 years both countries report, El Salvador has been ahead every year.
El Salvador ranks 10th and South-East Asia (WHO region) ranks 13th of 193 countries.
El Salvador has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | El Salvador | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 14.1% | 2.6% | 11.5% | El Salvador |
| 2000s | 23.2% | 5.7% | 17.6% | El Salvador |
| 2010s | 35.4% | 10.7% | 24.7% | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hypertension: effective treatment coverage (controlled hypertension), El Salvador or South-East Asia (WHO region)?
- El Salvador, at 39.5% against 13.3% in South-East Asia (WHO region) as of 2019.
- What is the difference in hypertension: effective treatment coverage (controlled hypertension) between El Salvador and South-East Asia (WHO region)?
- 26.2%, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and South-East Asia (WHO region)?
- 30 years are reported by both, from 1990 to 2019.
- How do El Salvador and South-East Asia (WHO region) rank globally for hypertension: effective treatment coverage (controlled hypertension)?
- El Salvador ranks 10th and South-East Asia (WHO region) ranks 13th of 193 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hypertension: effective treatment coverage (controlled hypertension) among adults aged 30-79 with hypertension, crude (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.